{"version":"1.0","provider_name":"Pharma Trend","provider_url":"https:\/\/pharma-trend.com\/en","author_name":"Business Wire","author_url":"https:\/\/pharma-trend.com\/en\/author\/business\/","title":"Foundation Medicine Announces Strategic Collaboration with Arvinas - Pharma Trend","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"mCvrkvgWDi\"><a href=\"https:\/\/pharma-trend.com\/en\/foundation-medicine-announces-strategic-collaboration-with-arvinas\/\">Foundation Medicine Announces Strategic Collaboration with Arvinas<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/pharma-trend.com\/en\/foundation-medicine-announces-strategic-collaboration-with-arvinas\/embed\/#?secret=mCvrkvgWDi\" width=\"600\" height=\"338\" title=\"&#8220;Foundation Medicine Announces Strategic Collaboration with Arvinas&#8221; &#8212; Pharma Trend\" data-secret=\"mCvrkvgWDi\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/pharma-trend.com\/en\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"Initial Goal of Collaboration is to Develop FoundationOne\u00aeLiquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas\u2019 Investigational Androgen Receptor-Targeting PROTAC\u00ae Protein Degrader CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;#ASCO22&#8211;Today Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced a collaboration with Arvinas, Inc., to develop FoundationOne\u00aeLiquid CDx as a companion diagnostic for use with Arvinas\u2019 bavdegalutamide ... [Read more...]","thumbnail_url":"https:\/\/mms.businesswire.com\/media\/20220605005082\/en\/794671\/21\/FMI_horizontal-slate_%282%29.jpg"}